References
- Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. DOI: https://doi.org/10.3322/caac.21660.
- Organization, W. H. Egypt Cancer https://gco.iarc.fr/today/data/factsheets/populations/818-egypt-fact-sheets.pdf (Accessed 10 October, 2021)
- Mokhtar, N.; Salama, A.; Badawy, O.; Khorshed, E.; Mohamed, G.; Ibrahim, M.; Abdelazim, H. Book Cancer Pathology Registry 2000-2011; Cairo University: Cairo, Egypt, 2016.
- Jones, P.; Droller, M. Pathways of Development and Progression in Bladder Cancer: New Correlations between Clinical Observations and Molecular Mechanisms. Semin Urol. 1993, 11, 177–192.
- Knowles, M. A.; Hurst, C. D. Molecular Biology of Bladder Cancer: New Insights into Pathogenesis and Clinical Diversity. Nat. Rev. Cancer. 2015, 15, 25–41. DOI: https://doi.org/10.1038/nrc3817.
- Minoli, M.; Kiener, M.; Thalmann, G. N.; Kruithof-de Julio, M.; Seiler, R. Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. Int. J. Mol. Sci. 2020, 21(16), 5670. DOI: https://doi.org/10.3390/ijms21165670.
- Bosschieter, J.; Nieuwenhuijzen, J. A.; van Ginkel, T.; Vis, A. N.; Witte, B.; Newling, D.; Beckers, G. M. A.; van Moorselaar, R. J. A. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 Patients. Europ. Urol. 2018, 73, 226–232. DOI: https://doi.org/10.1016/j.eururo.2017.06.038.
- Sarier, M.; Usta, S. S.; Turgut, H.; Öztürk, S. A.; Soylu, A.; Emek, M.; Kukul, E.; Bozcuk, H.; Sepin, N. Prognostic Value of HPV DNA in Urothelial Carcinoma of the Bladder: A Preliminary Report of 2-Year Follow-up Results. Urology Journal. 2021. DOI: https://doi.org/10.22037/uj.v18i.6429.
- Simion, C.; Cedano-Prieto, M. E.; Sweeney, C. The LRIG Family: Enigmatic Regulators of Growth Factor Receptor Signaling. Endocr. Relat. Cancer. 2014, 21, R431–443. DOI: https://doi.org/10.1530/erc-14-0179.
- Malik, U.; Javed, A. LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers. Curr. Cancer Drug Targets. 2017, 17, 3–16. DOI: https://doi.org/10.2174/156800961701161202200445.
- Abraira, V. E.; Satoh, T.; Fekete, D. M.; Goodrich, L. V. Vertebrate Lrig3-ErbB Interactions Occur in Vitro but are Unlikely to Play a Role in Lrig3-dependent Inner Ear Morphogenesis. PLoS One. 2010, 5, e8981. DOI: https://doi.org/10.1371/journal.pone.0008981.
- Nilsson, J.; Vallbo, C.; Guo, D.; Golovleva, I.; Hallberg, B.; Henriksson, R.; Hedman, H. Cloning, Characterization, and Expression of Human LIG1. Biochem. Biophys. Res. Commun. 2001, 284, 1155–1161. DOI: https://doi.org/10.1006/bbrc.2001.5092.
- Holmlund, C.; Nilsson, J.; Guo, D.; Starefeldt, A.; Golovleva, I.; Henriksson, R.; Hedman, H. Characterization and Tissue-specific Expression of Human LRIG2. Gene. 2004, 332, 35–43. DOI: https://doi.org/10.1016/j.gene.2004.02.002.
- Guo, D.; Holmlund, C.; Henriksson, R.; Hedman, H. The LRIG Gene Family Has Three Vertebrate Paralogs Widely Expressed in Human and Mouse Tissues and a Homolog in Ascidiacea. Genomics. 2004, 84(1), 157–165. DOI: https://doi.org/10.1016/j.ygeno.2004.01.013.
- Krig, S. R.; Frietze, S.; Simion, C.; Miller, J. K.; Fry, W. H.; Rafidi, H.; Kotelawala, L.; Qi, L.; Griffith, O. L.; Gray, J. W. Lrig1 Is an Estrogen-regulated Growth Suppressor and Correlates with Longer Relapse-free Survival in ERα-positive Breast Cancer. Mol. Cancer Res. 2011, 9, 1406–1417. DOI: https://doi.org/10.1158/1541-7786.MCR-11-0227.
- Thomasson, M.; Wang, B.; Hammarsten, P.; Dahlman, A.; Persson, J. L.; Josefsson, A.; Stattin, P.; Granfors, T.; Egevad, L.; Henriksson, R. LRIG1 and the Liar Paradox in Prostate Cancer: A Study of the Expression and Clinical Significance of LRIG1 in Prostate Cancer. Int. J. Cancer. 2011, 128(12), 2843–2852. DOI: https://doi.org/10.1002/ijc.25820.
- Hedman, H.; Lindström, A. K.; Tot, T.; Stendahl, U.; Henriksson, R.; Hellberg, D. LRIG2 in Contrast to LRIG1 Predicts Poor Survival in Early-stage Squamous Cell Carcinoma of the Uterine Cervix. Acta oncologica. 2010, 49(6), 812–815. DOI: https://doi.org/10.3109/0284186X.2010.492789.
- Holmlund, C.; Haapasalo, H.; Yi, W.; Raheem, O.; Brännström, T.; Bragge, H.; Henriksson, R.; Hedman, H. Cytoplasmic LRIG2 Expression Is Associated with Poor Oligodendroglioma Patient Survival. Neuropathology. 2009, 29(3), 242–247. DOI: https://doi.org/10.1111/j.1440-1789.2008.00970.x.
- Lindquist, D.; Kvarnbrink, S.; Henriksson, R.; Hedman, H. LRIG and Cancer Prognosis. Acta Oncol. 2014, 53, 1135–1142. DOI: https://doi.org/10.3109/0284186x.2014.953258.
- Hedman, H.; Henriksson, R. LRIG Inhibitors of Growth Factor signalling – Double-edged Swords in Human Cancer? Euro. J. Cancer. 2007, 43(4), 676–682. DOI: https://doi.org/10.1016/j.ejca.2006.10.021.
- Guo, D.; Nilsson, J.; Haapasalo, H.; Raheem, O.; Bergenheim, T.; Hedman, H.; Henriksson, R. Perinuclear Leucine-rich Repeats and Immunoglobulin-like Domain Proteins (LRIG1-3) as Prognostic Indicators in Astrocytic Tumors. Acta Neuropathologica. 2006, 111(3), 238–246. DOI: https://doi.org/10.1007/s00401-006-0032-5.
- Ghasimi, S.; Haapasalo, H.; Eray, M.; Korhonen, K.; Brännström, T.; Hedman, H.; Andersson, U. Immunohistochemical Analysis of LRIG Proteins in Meningiomas: Correlation between Estrogen Receptor Status and LRIG Expression. J. Neuro-oncol. 2012, 108(3), 435–441. DOI: https://doi.org/10.1007/s11060-012-0856-x.
- Wang, G.; Wu, J.; Song, H. LRIG2 Expression and Prognosis in Non-small Cell Lung Cancer. Oncology Letters. 2014, 8(2), 667–672. DOI: https://doi.org/10.3892/ol.2014.2157.
- Wu, X.; Hedman, H.; Bergqvist, M.; Bergström, S.; Henriksson, R.; Gullbo, J.; Lennartsson, J.; Hesselius, P.; Ekman, S. Expression of EGFR and LRIG Proteins in Oesophageal Carcinoma with Emphasis on Patient Survival and Cellular Chemosensitivity. Acta Oncologica. 2012, 51(1), 69–76. DOI: https://doi.org/10.3109/0284186X.2011.562239.
- Muller, S.; Lindquist, D.; Kanter, L.; Flores-Staino, C.; Henriksson, R.; Hedman, H.; Andersson, S. Expression of LRIG1 and LRIG3 Correlates with Human Papillomavirus Status and Patient Survival in Cervical Adenocarcinoma. Int J Oncol. 2013, 42(1), 247–252. DOI: https://doi.org/10.3892/ijo.2012.1702.
- Guo, D.; Han, L.; Shu, K.; Chen, J.; Lei, T. Down-regulation of Leucine-rich Repeats and Immunoglobulin-like Domain Proteins (LRIG1-3) in HP75 Pituitary Adenoma Cell Line. Journal of Huazhong University of Science and Technology. 2007, 27(1), 91–94. DOI: https://doi.org/10.1007/s11596-007-0126-x.
- Yang, H. K.; Chen, H.; Mao, F.; Xiao, Q. G.; Xie, R. F.; Lei, T. Downregulation of LRIG2 Expression Inhibits Angiogenesis of Glioma via EGFR/VEGF-A Pathway. Oncol. Lett. 2017, 14, 4021–4028. DOI: https://doi.org/10.3892/ol.2017.6671.
- Wang, B.; Han, L.; Chen, R.; Cai, M.; Han, F.; Lei, T.; Guo, D.-S. Down-regulation of LRIG2 Expression by RNA Interference Inhibits Glioblastoma Cell (GL15) Growth, Causes Cell Cycle Redistribution, Increases Cell Apoptosis and Enhances Cell Adhesion and Invasion in Vitro. Cancer Biol. Ther. 2009, 8(11), 1018–1023. DOI: https://doi.org/10.4161/cbt.8.11.8375.
- Yang, H.; Mao, F.; Zhang, H.; Wang, B.; Wan, F.; Guo, D.; Lei, T. Effect of Over-expressed LRIG3 on Cell Cycle and Survival of Glioma Cells. J Huazhong Univ Sci Technolog Med Sci. 2011, 31(5), 667. DOI: https://doi.org/10.1007/s11596-011-0579-9.
- Cai, M. J.; Xie, R. F.; Han, L.; Chen, R. D.; Wang, B. F.; Ye, F.; Guo, D. S.; Lei, T. Effect of RNAi-mediated LRIG3 Gene Silencing on Proliferation of Glioma GL15 Cells and Expression of PCNA and Ki-67. Ai Zheng. 2009, 28, 1–4.
- Qi, Y.; Chang, L.; Li, H.; Yu, G.; Xiao, W.; Xia, D.; Guan, W.; Yang, Y.; Lang, B.; Deng, K.-L. Over-expression of LRIG3 Suppresses Growth and Invasion of Bladder Cancer Cells. Journal of Huazhong University of Science and Technology [Medical Sciences]. 2013, 33(1), 111–116. DOI: https://doi.org/10.1007/s11596-013-1081-3.
- Zhang, S.; Wang, J.; Zhang, X.; Zhou, F. Tumor-infiltrating CD8+ Lymphocytes Predict Different Clinical Outcomes in Organ-and Non-organ-confined Urothelial Carcinoma of the Bladder following Radical Cystectomy. PeerJ. 2017, 5, e3921. DOI: https://doi.org/10.7717/peerj.3921.
- Moch, H.; Humphrey, P. A.; Ulbright, T. M.; Reuter, V. E. Book WHO Classification of Tumours of the Urinary System and Male Genital Organs; International Agency for Research on Cancer: Lyon, 2016.
- Kindler, T.; Breitenbuecher, F.; Marx, A.; Beck, J.; Hess, G.; Weinkauf, B.; Duyster, J.; Peschel, C.; Kirkpatrick, C. J.; Theobald, M. Efficacy and Safety of Imatinib in Adult Patients with C-kit–positive Acute Myeloid Leukemia. Blood. 2004, 103(10), 3644–3654. DOI: https://doi.org/10.1182/blood-2003-06-2071.
- Yuan, X.; Bao, S.; Yang, W.; Ye, Z. Effect of Silencing LRIG3 Gene on the Proliferation and Apoptosis of Bladder Cancer T24 Cells. J Huazhong Univ Sci Technolog Med Sci. 2011, 31(2), 220. DOI: https://doi.org/10.1007/s11596-011-0256-z.
- Chen, Y.; Wang, Q.; Wang, M.; Li, M. Overexpressed LRIG3 Gene Ameliorates Prostate Cancer through Suppression of Cell Invasion and Migration. Int. J. Biol. Macromol. 2019, 124, 1–9. DOI: https://doi.org/10.1016/j.ijbiomac.2018.11.028.
- Zeng, K.; Chen, X.; Xu, M.; Liu, X.; Li, C.; Xu, X.; Pan, B.; Qin, J.; He, B.; Pan, Y., et al. LRIG3 Represses Cell Motility by Inhibiting Slug via Inactivating ERK Signaling in Human Colorectal Cancer. IUBMB Life.2020, 72(7), 1393–1403. DOI: https://doi.org/10.1002/iub.2262.
- Guo, D.; Yang, H.; Guo, Y.; Xiao, Q.; Mao, F.; Tan, Y.; Wan, X.; Wang, B.; Lei, T. LRIG3 Modulates Proliferation, Apoptosis and Invasion of Glioblastoma Cells as a Potent Tumor Suppressor. J. Neurol. Sci. 2015, 350(1–2), 61–68. DOI: https://doi.org/10.1016/j.jns.2015.02.015.
- Razumova, Z.; Oda, H.; Govorov, I.; Lundin, E.; Östensson, E.; Lindquist, D.; Mints, M. The Prognostic Role of LRIG Proteins in Endometrial Cancer. Cancers (Basel). 2021, 13(6), 1361. DOI: https://doi.org/10.3390/cancers13061361.
- Donnini, S.; Morbidelli, L.; Taraboletti, G.; Ziche, M. ERK1-2 and P38 MAPK Regulate MMP/TIMP Balance and Function in Response to Thrombospondin-1 Fragments in the Microvascular Endothelium. Life Sci. 2004, 74(24), 2975–2985. DOI: https://doi.org/10.1016/j.lfs.2003.09.075.
- Hoesl, C.; Fröhlich, T.; Hundt, J. E.; Kneitz, H.; Goebeler, M.; Wolf, R.; Schneider, M. R.; Dahlhoff, M. The Transmembrane Protein LRIG2 Increases Tumor Progression in Skin Carcinogenesis. Mol. Oncol. 2019, 13, 2476–2492. DOI: https://doi.org/10.1002/1878-0261.12579.
- Avraham, R.; Yarden, Y. Feedback Regulation of EGFR Signalling: Decision Making by Early and Delayed Loops. Nat. Rev. Mol. Cell Biol. 2011, 12, 104–117. DOI: https://doi.org/10.1038/nrm3048.
- Casaletto, J. B.; McClatchey, A. I. Spatial Regulation of Receptor Tyrosine Kinases in Development and Cancer. Nat. Rev. Cancer. 2012, 12, 387–400. DOI: https://doi.org/10.1038/nrc3277.
- Xiao, Q.; Tan, Y.; Guo, Y.; Yang, H.; Mao, F.; Xie, R.; Wang, B.; Lei, T.; Guo, D. Soluble LRIG2 Ectodomain Is Released from Glioblastoma Cells and Promotes the Proliferation and Inhibits the Apoptosis of Glioblastoma Cells in Vitro and in Vivo in a Similar Manner to the Full-length LRIG2. PLoS One. 2014, 9, e111419. DOI: https://doi.org/10.1371/journal.pone.0111419.
- Xiao, Q.; Dong, M.; Cheng, F.; Mao, F.; Zong, W.; Wu, K.; Wang, H.; Xie, R.; Wang, B.; Lei, T. LRIG2 Promotes the Proliferation and Cell Cycle Progression of Glioblastoma Cells in Vitro and in Vivo through Enhancing PDGFRβ Signaling. Int. J. Oncol. 2018, 53, 1069–1082. DOI: https://doi.org/10.3892/ijo.2018.4482.
- Gakis, G.; Efstathiou, J.; Lerner, S. P.; Cookson, M. S.; Keegan, K. A.; Guru, K. A.; Shipley, W. U.; Heidenreich, A.; Schoenberg, M. P.; Sagaloswky, A. I. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-invasive Urothelial Carcinoma of the Bladder. Europ. Urol. 2013, 63, 45–57. DOI: https://doi.org/10.1016/j.eururo.2012.08.009.
- Gore, J. L.; Lai, J.; Setodji, C. M.; Litwin, M. S.; Saigal, C. S. Mortality Increases When Radical Cystectomy Is Delayed More than 12 Weeks: Results from a Surveillance, Epidemiology, and End Results–Medicare Analysis. Cancer. 2009, 115, 988–996. DOI: https://doi.org/10.1002/cncr.24052.
- Lindström, A. K.; Hellberg, D. Immunohistochemical LRIG3 Expression in Cervical Intraepithelial Neoplasia and Invasive Squamous Cell Cervical Cancer: Association with Expression of Tumor Markers, Hormones, High-risk HPV-infection, Smoking and Patient Outcome. Eur J Histochem. 2014, 58, 2227. DOI: https://doi.org/10.4081/ejh.2014.2227.
- Ranhem, C.; Lillsunde Larsson, G.; Hedman, H.; Lindquist, D.; Karlsson, M. G.; Hellström, A. C.; Östensson, E.; Sorbe, B.; Hellman, K.; Andersson, S. Expression of LRIG Proteins as Possible Prognostic Factors in Primary Vaginal Carcinoma. PLoS One. 2017, 12, e0183816. DOI: https://doi.org/10.1371/journal.pone.0183816.
- Cai, M.; Xie, R.; Han, L.; Chen, R.; Wang, B.; Ye, F.; Guo, D.; Lei, T. Effects of RNAi-mediated Gene Silencing of LRIG3 Expression on Cell Cycle and Survival of Glioma Cells. J Huazhong Univ Sci Technolog Med Sci. 2009, 29, 88–93. DOI: https://doi.org/10.1007/s11596-009-0119-z.
- Stefansson, K.; Oda, H.; Öfverman, C.; Lundin, E.; Hedman, H.; Lindquist, D. LRIG1‑2 and LMO7 Immunoreactivity in Vulvar Squamous Cell Carcinoma: Association with Prognosis in Relation to HPV‑DNA and p16INK4a Status. Oncol Rep. 2019, 42, 142–150. DOI: https://doi.org/10.3892/or.2019.7138.
- Yang, Z.; Xie, C.; Xu, W.; Liu, G.; Cao, X.; Li, W.; Chen, J.; Zhu, Y.; Luo, S.; Luo, Z. Phosphorylation and Inactivation of PTEN at Residues Ser380/Thr382/383 Induced by Helicobacter Pylori Promotes Gastric Epithelial Cell Survival through PI3K/Akt Pathway. Oncotarget. 2015, 6, 31916. DOI: https://doi.org/10.18632/oncotarget.5577.